These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28497489)

  • 1. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression.
    Kumada H; Mochida S; Nakamuta M; Suzuki F; Yagi T; Takasaki R; Okai M; Kamiya N; Okada Y; Hirota S; Orihashi M; Ochi M; Chayama K
    Hepatol Res; 2018 Feb; 48(2):184-192. PubMed ID: 28497489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.
    Kumada H; Suzuki F; Kamiya N; Orihashi M; Nakayasu Y; Yamada I
    Hepatol Res; 2017 May; 47(6):514-521. PubMed ID: 27062488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.
    Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Wakabayashi H; Ohkoshi S; Tsukishiro T; Takahashi T; Watanabe T; Terai S
    World J Hepatol; 2017 Feb; 9(5):252-262. PubMed ID: 28261382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.
    Yamagiwa Y; Asano M; Kawasaki Y; Korenaga M; Murata K; Kanto T; Mizokami M; Masaki N
    Cytokine; 2016 Dec; 88():29-36. PubMed ID: 27541605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    Flisiak R; Shiffman M; Arenas J; Cheinquer H; Nikitin I; Dong Y; Rana K; Srinivasan S
    PLoS One; 2016; 11(10):e0164563. PubMed ID: 27749900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
    Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T; Takahashi S; Tatsukawa Y; Hiramatsu A; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ide K; Tashiro H; Ohdan H; Chayama K
    Hepatol Res; 2014 Nov; 44(12):1259-64. PubMed ID: 24382214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis.
    Quigley JM; Bryden PA; Scott DA; Kuwabara H; Cerri K
    Hepatol Res; 2015 Oct; 45(10):E89-98. PubMed ID: 25559771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.
    Kumada H; Sato K; Takehara T; Nakamuta M; Ishigami M; Chayama K; Toyota J; Suzuki F; Nakayasu Y; Ochi M; Yamada I; Okanoue T
    Hepatol Res; 2015 Jul; 45(7):745-54. PubMed ID: 25196718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
    Vo KP; Vutien P; Akiyama MJ; Vu VD; Ha NB; Piotrowski JI; Wantuck J; Roytman MM; Tsai N; Cheung R; Li J; Nguyen MH
    Dig Dis Sci; 2015 Apr; 60(4):1045-51. PubMed ID: 25821099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.